Efficacy of bevacizumab in combination with paclitaxel for metastatic breast cancer

Shuhei Suzuki, Kenichi Sakurai, Saki Nagashima, Yukiko Hara, Sadao Amano, Katsuhisa Enomoto, Makoto Makishima

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


Bevacizumab is a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody that inhibits angiogenesis. In this study, we examined bevacizumab plus paclitaxel therapy for metastatic breast cancer. We divided 20 patients into hormone-positive (estrogen receptor [ER] +or progesterone receptor [PgR] +) and hormone-negative groups (ER-and PgR-). The average number of bevacizumab plus paclitaxel therapy cycles was 3.35 (range, 1-14). The response rates for the hormone-positive and hormone-negative groups were 6.6% and 20%, respectively. Although the response rate was low in all cases, one patient who received first-line bevacizumab plus paclitaxel therapy was evaluated PR.

Original languageEnglish
Pages (from-to)1289-1291
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Issue number10
Publication statusPublished - 1 Oct 2014


  • Bevacizumab
  • Breast cancer
  • VEGF


Dive into the research topics of 'Efficacy of bevacizumab in combination with paclitaxel for metastatic breast cancer'. Together they form a unique fingerprint.

Cite this